Rituxan: payments to doctors
Payments that named Rituxan as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $67.5M
- Providers
- 3,435
- Transactions
- 18,107
- Average per transaction
- $3,727
The per-transaction average — $3,727 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,435 providers the average total is $19,646, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $66,103,739 | 98.0% |
| Genentech USA, Inc. | $1,312,348 | 1.9% |
| Bristol Myers Squibb | $51,036 | 0.1% |
| Chugai Pharmaceutical Co., Ltd. | $11,382 | 0.0% |
| F. Hoffmann-la Roche AG | $6,383 | 0.0% |
| Biogen | $50 | 0.0% |